内电解组合工艺处理重度富营养化水体的初步中试试验

采用催化铁内电解-沸石床-生物活性炭组合工艺进行了处理重度富营养化水的中试试验.通过对进水与出水浊度、TP、CODMn、UV254、总铁、NH3-N、和NO2--N的监测,研究了本组合工艺对重度富营养化水体的处理性能.试验期间,水温约在10℃.初步结果表明,本组合工艺对浊度、TP、CODMn和UV254均有较好的去除作用,平均去除率达到50%以上,出水中铁含量均低于进水.由于水温过低,未观察到氨氮和亚硝酸盐氮的明显变化.     

小康居住区的水环境与水质净化工程

分析了小康居住区水环境的含义，组成，并对居住区水质净化工程中3个热点问题（优质饮水，污水处理和中水回用等）进行了较深入的分析，建议小康居住区优质饮水供应以小区纯水站净化，管理输送至用户方式为主；不居住区的污水处理应分3种情况区别对待，在居住区污水处理达到排放标准的基础上，进一步处理回用，是经济合理的。     

用神经网络辨识化学强化一级处理系统

运用实验室得到的数据为样本 ,选取了CODCr和絮凝剂投加量为指标 ,采用三层结构的神经网络 ,利用Matlab的神经网络工具箱中的批处理梯度下降法对CEPT系统经行辨识。辨识结果表明 :模型的预测值与实测值的平均误差在 3 .7%左右 ,具有较高的精度。同时 ,该模型还具有适应性强 ,使用方便 ,高效的特点 ,为CEPT系统的在线实时控制提供了一条有效的途径。     

MSAFP levels and oesophageal atresia

This study was undertaken to evaluate the relationship between maternal serum alpha-fetoprotein (MSAFP) levels and oesophageal atresia (OA). OA occurred in 16 fetuses of mothers who had an MSAFP test in the study interval. The multiple of the median (MOM) value for MSAFP averaged 1·54 ± 0·65 (range 0·5–2·9 MOM), which was significantly higher than the value seen in controls. The median MOM was 1·35. Using a cut-off of 2·5 MOM, the sensitivity of MSAFP for detecting OA was 19 per cent. Although OA should be considered in the differential diagnosis of an elevated MSAFP level, MSAFP cannot be considered an appropriate screening test for OA given the low sensitivity.     

Serum PAPP-A levels are depressed in women with fetal Down syndrome in early pregnancy

The value of maternal serum pregnancy-associated plasma protein (PAPP)-A in screening for Down syndrome in early pregnancy was assessed using stored samples. Seventeen cases of Down syndrome and 66 unaffected control pregnancies were studied. The median PAPP-A level in the cases was 0.42 multiples of the expected value in controls (p <0.0001). Eleven cases (65 per cent) had levels less than half the expected value compared with only six controls (9 per cent). A commercial assay kit is now needed so that prospective screening with this marker can begin.     

Expanding multiple marker screening for Down's syndrome to include Edward'S syndrome

Information on maternal age and maternal serum alpha-fetoprotein, unconjugated oestriol (uE₃), and human chorionic gonadotrophin (hCG) levels was used to investigate retrospectively the effect of estimating Edward's syndrome risk in women having multi-marker screening for Down's syndrome. The screened population comprised 15 pregnancies affected by Edward's syndrome, 15 with Down's syndrome and 5472 unaffected pregnancies. The use of all three markers to estimate Edward's syndrome risk would have led to the detection of 10–12 (67–80 per cent) cases with a false-positive rate of 0.3–0.6 per cent depending on the risk cut-off. A further case would have been detected as a result of screening for Down's syndrome alone. Similar results were obtained when the Edward's syndrome risk was based on uE₃ and hCG only. These data suggest that extending Down's syndrome screening to include Edward's syndrome risk will yield a high detection rate with only a small increase in the false-positive rate.     

Dystrophin protein and rflp analyis for fetal diagnosis and carrier confirmation of duchenne muscular dystrophy

A pregnant woman with indeterminate Duchenne muscular dystrophy (DMD) carrier status, but with DMD diagnosed in her deceased brother (unavailable for study), presented for prenatal diagnosis, intending to continue the pregnancy only if proven unaffected with DMD with near absolute certainty. Creatine kinase (CK) assays to clarify carrier status were inconclusive. Male sex in the fetus was identified, but DNA restriction fragment length polymorphism (RFLP) analysis was not yet available to this centre to investigate the possible transmission of the DMD gene, and the pregnancy was terminated. Tissue histology and dystrophin protein analysis demonstrated the absence of DMD. In a situation with proven maternal carrier status, future fetal inheritance of the opposite maternal X chromosome would indicate the presence of DMD. However, maternal carrier status remained in doubt through a second pregnancy, even with RFLP studies, and was finally established when dystrophin analysis confirmed the presence of DMD in the second fetus. Histologic findings are presented, contrasting features in the two fetuses. The value of dystrophin analysis for establishing the diagnosis of fetal DMD, in this case proving maternal carrier status in a difficult situation, and for demonstrating DMD gene:RFLP haplotype relationships is illustrated.